Skip to main content
SpringerLink
Log in

Novel and Emerging Chemotherapeutic Agents in Head and Neck Cancer

  • Chapter
  • First Online:
Improving Outcomes in Oral Cancer

  • 468 Accesses

Abstract

Despite the advancements in the treatment of squamous head and neck cancer in the past decade, clinical outcomes still remain poor. The use of multimodality treatment and the advent of targeted therapies have improved outcomes. This chapter will provide a brief overview of the current management for squamous head and neck cancers in both the locally advanced and metastatic settings. We will then outline targeted therapies currently in use or under investigation for the treatment of both locally advanced and metastatic head and neck cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Wheless SA, McKinney KA, Zanation AM. A prospective study of the clinical impact of a multidisciplinary head and neck tumor board. Otolaryngol Head Neck Surg. 2010;143(5):650–4.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Wuthrick EJ, Zhang Q, Machtay M, Rosenthal DI, Nguyen-Tan PF, Fortin A, et al. Institutional clinical trial accrual volume and survival of patients with head and neck cancer. J Clin Oncol. 2015;33(2):156–64.

    Article  PubMed  Google Scholar 

  3. Posner MR, Hershock DM, Blajman CR, Mickiewicz E, Winquist E, Gorbounova V, et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med. 2007;357(17):1705–15.

    Article  PubMed  Google Scholar 

  4. Brockstein B, Haraf DJ, Rademaker AW, Kies MS, Stenson KM, Rosen F, et al. Patterns of failure, prognostic factors and survival in locoregionally advanced head and neck cancer treated with concomitant chemoradiotherapy: a 9-year, 337-patient, multi-institutional experience. Ann Oncol. 2004;15(8):1179–86.

    Article  PubMed  Google Scholar 

  5. Bourhis J, Le Maitre A, Baujat B, Audry H, Pignon JP. Meta-analysis of chemotherapy in head NCCG, et al. Individual patients’ data meta-analyses in head and neck cancer. Curr Opin Oncol. 2007;19(3):188–94.

    Article  PubMed  Google Scholar 

  6. Alvi A, Johnson JT. Development of distant metastasis after treatment of advanced-stage head and neck cancer. Head Neck. 1997;19(6):500–5.

    Article  PubMed  Google Scholar 

  7. Bhatia R, Bahadur S. Distant metastasis in malignancies of the head and neck. J Laryngol Otol. 1987;101(9):925–8.

    Article  PubMed  Google Scholar 

  8. Garavello W, Ciardo A, Spreafico R, Gaini RM. Risk factors for distant metastases in head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg. 2006;132(7):762–6.

    Article  PubMed  Google Scholar 

  9. Pignon JP, le Maitre A, Maillard E, Bourhis J, Group M-NC. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol. 2009;92(1):4–14.

    Article  PubMed  Google Scholar 

  10. Haddad R, O'Neill A, Rabinowits G, Tishler R, Khuri F, Adkins D, et al. Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial. Lancet Oncol. 2013;14(3):257–64.

    Article  PubMed  Google Scholar 

  11. Hitt R, Grau JJ, Lopez-Pousa A, Berrocal A, Garcia-Giron C, Irigoyen A, et al. A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer. Ann Oncol. 2014;25(1):216–25.

    Article  PubMed  Google Scholar 

  12. Cohen EE, Karrison TG, Kocherginsky M, Mueller J, Egan R, Huang CH, et al. Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer. J Clin Oncol. 2014;32(25):2735–43.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Ghi MG, Paccagnella A, Ferrari D, Foa P, Alterio D, Codeca C, et al. Induction TPF followed by concomitant treatment versus concomitant treatment alone in locally advanced head and neck cancer. A phase II-III trial. Ann Oncol. 2017;28(9):2206–12.

    PubMed  Google Scholar 

  14. Lorch JH, Goloubeva O, Haddad RI, Cullen K, Sarlis N, Tishler R, et al. Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial. Lancet Oncol. 2011;12(2):153–9.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Vermorken JB, Remenar E, van Herpen C, Gorlia T, Mesia R, Degardin M, et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med. 2007;357(17):1695–704.

    Article  PubMed  Google Scholar 

  16. Blanchard P, Bourhis J, Lacas B, Posner MR, Vermorken JB, Cruz Hernandez JJ, et al. Taxane-cisplatin-fluorouracil as induction chemotherapy in locally advanced head and neck cancers: an individual patient data meta-analysis of the meta-analysis of chemotherapy in head and neck cancer group. J Clin Oncol. 2013;31(23):2854–60.

    Article  PubMed  Google Scholar 

  17. Adelstein DJ, Li Y, Adams GL, Wagner H Jr, Kish JA, Ensley JF, et al. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol. 2003;21(1):92–8.

    Article  PubMed  Google Scholar 

  18. Forastiere AA, Goepfert H, Maor M, Pajak TF, Weber R, Morrison W, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med. 2003;349(22):2091–8.

    Article  PubMed  Google Scholar 

  19. Fountzilas G, Ciuleanu E, Dafni U, Plataniotis G, Kalogera-Fountzila A, Samantas E, et al. Concomitant radiochemotherapy vs radiotherapy alone in patients with head and neck cancer: a Hellenic Cooperative Oncology Group Phase III Study. Med Oncol. 2004;21(2):95–107.

    Article  PubMed  Google Scholar 

  20. Posner MR, Norris CM, Wirth LJ, Shin DM, Cullen KJ, Winquist EW, et al. Sequential therapy for the locally advanced larynx and hypopharynx cancer subgroup in TAX 324: survival, surgery, and organ preservation. Ann Oncol. 2009;20(5):921–7.

    Article  PubMed  Google Scholar 

  21. Bourhis J, Sire C, Graff P, Gregoire V, Maingon P, Calais G, et al. Concomitant chemoradiotherapy versus acceleration of radiotherapy with or without concomitant chemotherapy in locally advanced head and neck carcinoma (GORTEC 99-02): an open-label phase 3 randomised trial. Lancet Oncol. 2012;13(2):145–53.

    Article  PubMed  Google Scholar 

  22. Clavel M, Vermorken JB, Cognetti F, Cappelaere P, de Mulder PH, Schornagel JH, et al. Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinoma of the head and neck. A phase III study of the EORTC Head and Neck Cancer Cooperative Group. Ann Oncol. 1994;5(6):521–6.

    Article  PubMed  Google Scholar 

  23. Forastiere AA, Metch B, Schuller DE, Ensley JF, Hutchins LF, Triozzi P, et al. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study. J Clin Oncol. 1992;10(8):1245–51.

    Article  PubMed  Google Scholar 

  24. Jacobs C, Lyman G, Velez-Garcia E, Sridhar KS, Knight W, Hochster H, et al. A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol. 1992;10(2):257–63.

    Article  PubMed  Google Scholar 

  25. Gibson MK, Li Y, Murphy B, Hussain MH, DeConti RC, Ensley J, et al. Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2005;23(15):3562–7.

    Article  PubMed  Google Scholar 

  26. Rivera F, Garcia-Castano A, Vega N, Vega-Villegas ME, Gutierrez-Sanz L. Cetuximab in metastatic or recurrent head and neck cancer: the EXTREME trial. Expert Rev Anticancer Ther. 2009;9(10):1421–8.

    Article  PubMed  Google Scholar 

  27. Dorsey K, Agulnik M. Promising new molecular targeted therapies in head and neck cancer. Drugs. 2013;73(4):315–25.

    Article  PubMed  Google Scholar 

  28. Hynes NE, Horsch K, Olayioye MA, Badache A. The ErbB receptor tyrosine family as signal integrators. Endocr Relat Cancer. 2001;8(3):151–9.

    Article  PubMed  Google Scholar 

  29. Kruger JS, Reddy KB. Distinct mechanisms mediate the initial and sustained phases of cell migration in epidermal growth factor receptor-overexpressing cells. Mol Cancer Res. 2003;1(11):801–9.

    PubMed  Google Scholar 

  30. Masuda M, Toh S, Koike K, Kuratomi Y, Suzui M, Deguchi A, et al. The roles of JNK1 and Stat3 in the response of head and neck cancer cell lines to combined treatment with all-trans-retinoic acid and 5-fluorouracil. Jpn J Cancer Res. 2002;93(3):329–39.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer. 2002;2(7):489–501.

    Article  PubMed  Google Scholar 

  32. Ellerbroek SM, Halbleib JM, Benavidez M, Warmka JK, Wattenberg EV, Stack MS, et al. Phosphatidylinositol 3-kinase activity in epidermal growth factor-stimulated matrix metalloproteinase-9 production and cell surface association. Cancer Res. 2001;61(5):1855–61.

    PubMed  Google Scholar 

  33. Agulnik M. New approaches to EGFR inhibition for locally advanced or metastatic squamous cell carcinoma of the head and neck (SCCHN). Med Oncol. 2012;29(4):2481–91.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006;354(6):567–78.

    Article  PubMed  Google Scholar 

  35. Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol. 2010;11(1):21–8.

    Article  PubMed  Google Scholar 

  36. Ang KK, Zhang Q, Rosenthal DI, Nguyen-Tan PF, Sherman EJ, Weber RS, et al. Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522. J Clin Oncol. 2014;32(27):2940–50.

    Article  PubMed  PubMed Central  Google Scholar 

  37. Saloura V, Vokes EE. EGFR-based bioradiotherapy in SCCHN. Lancet Oncol. 2015;16(2):129–30.

    Article  PubMed  Google Scholar 

  38. Mesia R, Henke M, Fortin A, Minn H, Yunes Ancona AC, Cmelak A, et al. Chemoradiotherapy with or without panitumumab in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-1): a randomised, controlled, open-label phase 2 trial. Lancet Oncol. 2015;16(2):208–20.

    Article  PubMed  Google Scholar 

  39. Siu LL, Waldron JN, Chen BE, Winquist E, Wright JR, Nabid A, et al. Effect of standard radiotherapy with cisplatin vs accelerated radiotherapy with panitumumab in locoregionally advanced squamous cell head and neck carcinoma: a randomized clinical trial. JAMA Oncol. 2017;3(2):220–6.

    Article  PubMed  Google Scholar 

  40. Giralt J, Trigo J, Nuyts S, Ozsahin M, Skladowski K, Hatoum G, et al. Panitumumab plus radiotherapy versus chemoradiotherapy in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-2): a randomised, controlled, open-label phase 2 trial. Lancet Oncol. 2015;16(2):221–32.

    Article  PubMed  Google Scholar 

  41. Vermorken JB, Stohlmacher-Williams J, Davidenko I, Licitra L, Winquist E, Villanueva C, et al. Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial. Lancet Oncol. 2013;14(8):697–710.

    Article  PubMed  Google Scholar 

  42. Bastholt L, Specht L, Jensen K, Brun E, Loft A, Petersen J, et al. Phase I/II clinical and pharmacokinetic study evaluating a fully human monoclonal antibody against EGFr (HuMax-EGFr) in patients with advanced squamous cell carcinoma of the head and neck. Radiother Oncol. 2007;85(1):24–8.

    Article  PubMed  Google Scholar 

  43. Machiels JP, Subramanian S, Ruzsa A, Repassy G, Lifirenko I, Flygare A, et al. Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: an open-label, randomised phase 3 trial. Lancet Oncol. 2011;12(4):333–43.

    Article  PubMed  Google Scholar 

  44. Schick U, Gujral DM, Richards TM, Harrington KJ, Nutting CM. Zalutumumab in head and neck cancer. Expert Opin Biol Ther. 2012;12(1):119–25.

    Article  PubMed  Google Scholar 

  45. Argiris A, Ghebremichael M, Gilbert J, Lee JW, Sachidanandam K, Kolesar JM, et al. Phase III randomized, placebo-controlled trial of docetaxel with or without gefitinib in recurrent or metastatic head and neck cancer: an eastern cooperative oncology group trial. J Clin Oncol. 2013;31(11):1405–14.

    Article  PubMed  PubMed Central  Google Scholar 

  46. Cohen EE, Rosen F, Stadler WM, Recant W, Stenson K, Huo D, et al. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol. 2003;21(10):1980–7.

    Article  PubMed  Google Scholar 

  47. Martins RG, Parvathaneni U, Bauman JE, Sharma AK, Raez LE, Papagikos MA, et al. Cisplatin and radiotherapy with or without erlotinib in locally advanced squamous cell carcinoma of the head and neck: a randomized phase II trial. J Clin Oncol. 2013;31(11):1415–21.

    Article  PubMed  Google Scholar 

  48. Harrington KJ, Berrier A, Robinson M, Remenar E, Housset M, Mendoza FH, et al. Phase II study of oral lapatinib, a dual-tyrosine kinase inhibitor, combined with chemoradiotherapy (CRT) in patients (pts) with locally advanced, unresected squamous cell carcinoma of the head and neck (SCCHN). J Clin Oncol. 2010;28(15 Suppl):5505.

    Article  Google Scholar 

  49. Abidoye OO, Cohen EE, Wong SJ, Kozloff MF, Nattam SR, Stenson KM, et al. A phase II study of lapatinib (GW572016) in recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN). J Clin Oncol. 2006;24(18 Suppl):5568.

    Google Scholar 

  50. Seiwert TY, Fayette J, Cupissol D, del Campo JM, Clement PM, Hitt R, et al. A randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck†. Ann Oncol. 2014;25(9):1813–20.

    Article  PubMed  PubMed Central  Google Scholar 

  51. Abdul Razak AR, Soulières D, Laurie SA, Hotte SJ, Singh S, Winquist E, et al. A phase II trial of dacomitinib, an oral pan-human EGF receptor (HER) inhibitor, as first-line treatment in recurrent and/or metastatic squamous-cell carcinoma of the head and neck†. Ann Oncol. 2013;24(3):761–9.

    Article  PubMed  Google Scholar 

  52. Kim HS, Kwon HJ, Jung I, Yun MR, Ahn M-J, Kang BW, et al. Phase II clinical and exploratory biomarker study of dacomitinib in patients with recurrent and/or metastatic squamous cell carcinoma of head and neck. Clin Cancer Res. 2015;21(3):544–52.

    Article  PubMed  Google Scholar 

  53. Kyzas PA, Stefanou D, Batistatou A, Agnantis NJ. Prognostic significance of VEGF immunohistochemical expression and tumor angiogenesis in head and neck squamous cell carcinoma. J Cancer Res Clin Oncol. 2005;131(9):624–30.

    Article  PubMed  Google Scholar 

  54. Brands RC, Knierim LM, De Donno F, Steinacker V, Hartmann S, Seher A, et al. Targeting VEGFR and FGFR in head and neck squamous cell carcinoma in vitro. Oncol Rep. 2017;38(3):1877–85.

    Article  PubMed  Google Scholar 

  55. Swiecicki PL, Zhao L, Belile E, Sacco AG, Chepeha DB, Dobrosotskaya I, et al. A phase II study evaluating axitinib in patients with unresectable, recurrent or metastatic head and neck cancer. Investig New Drugs. 2015;33(6):1248–56.

    Article  Google Scholar 

  56. Hsu HW, de Necochea-Campion R, Williams V, Duerksen-Hughes PJ, Simental AA Jr, Ferris RL, et al. Linifanib (ABT-869), enhances cytotoxicity with poly (ADP-ribose) polymerase inhibitor, veliparib (ABT-888), in head and neck carcinoma cells. Oral Oncol. 2014;50(7):662–9.

    Article  PubMed  Google Scholar 

  57. Kramer B, Hock C, Birk R, Sauter A, Stuck BA, Hormann K, et al. Targeted therapies in HPV-positive and -negative HNSCC – alteration of EGFR and VEGFR-2 expression in vitro. Anticancer Res. 2016;36(6):2799–807.

    PubMed  Google Scholar 

  58. Argiris A, Bauman JE, Ohr J, Gooding WE, Heron DE, Duvvuri U, et al. Phase II randomized trial of radiation therapy, cetuximab, and pemetrexed with or without bevacizumab in patients with locally advanced head and neck cancer. Ann Oncol. 2016;27(8):1594–600.

    Article  PubMed  PubMed Central  Google Scholar 

  59. Fury MG, Xiao H, Sherman EJ, Baxi S, Smith-Marrone S, Schupak K, et al. Phase II trial of bevacizumab + cetuximab + cisplatin with concurrent intensity-modulated radiation therapy for patients with stage III/IVB head and neck squamous cell carcinoma. Head Neck. 2016;38(Suppl 1):E566–70.

    Article  PubMed  Google Scholar 

  60. Argiris A, Karamouzis MV, Gooding WE, Branstetter BF, Zhong S, Raez LE, et al. Phase II trial of pemetrexed and bevacizumab in patients with recurrent or metastatic head and neck cancer. J Clin Oncol. 2011;29(9):1140–5.

    Article  PubMed  PubMed Central  Google Scholar 

  61. Williamson SK, Moon J, Huang CH, Guaglianone PP, LeBlanc M, Wolf GT, et al. Phase II evaluation of sorafenib in advanced and metastatic squamous cell carcinoma of the head and neck: Southwest Oncology Group Study S0420. J Clin Oncol. 2010;28(20):3330–5.

    Article  PubMed  PubMed Central  Google Scholar 

  62. Elser C, Siu LL, Winquist E, Agulnik M, Pond GR, Chin SF, et al. Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma. J Clin Oncol. 2007;25(24):3766–73.

    Article  PubMed  Google Scholar 

  63. Blumenschein GR, Glisson BS, Lu C, Sabichi AL, Ginsberg LE, Bartos CI, et al. Final results of a phase II study of sorafenib in combination with carboplatin and paclitaxel in patients with metastatic or recurrent squamous cell cancer of the head and neck (SCCHN). J Clin Oncol. 2012;30(15 Suppl):5592.

    Google Scholar 

  64. Machiels JP, Henry S, Zanetta S, Kaminsky MC, Michoux N, Rommel D, et al. Phase II study of sunitinib in recurrent or metastatic squamous cell carcinoma of the head and neck: GORTEC 2006-01. J Clin Oncol. 2010;28(1):21–8.

    Article  PubMed  Google Scholar 

  65. Choong NW, Kozloff M, Taber D, Hu HS, Wade J 3rd, Ivy P, et al. Phase II study of sunitinib malate in head and neck squamous cell carcinoma. Investig New Drugs. 2010;28(5):677–83.

    Article  Google Scholar 

  66. Papadimitrakopoulou VA, Frank SJ, Cohen EW, Hirsch FR, Myers JN, Heymach JV, et al. Phase I study of vandetanib with radiation therapy with or without cisplatin in locally advanced head and neck squamous cell carcinoma. Head Neck. 2016;38(3):439–47.

    Article  PubMed  Google Scholar 

  67. Sano D, Matsumoto F, Valdecanas DR, Zhao M, Molkentine DP, Takahashi Y, et al. Vandetanib restores head and neck squamous cell carcinoma cells’ sensitivity to cisplatin and radiation in vivo and in vitro. Clin Cancer Res. 2011;17(7):1815–27.

    Article  PubMed  PubMed Central  Google Scholar 

  68. Zibelman M, Mehra R. Overview of current treatment options and investigational targeted therapies for locally advanced squamous cell carcinoma of the head and neck. Am J Clin Oncol. 2016;39(4):396–406.

    Article  PubMed  Google Scholar 

  69. Chawla A, Adkins D, Worden FP, Rao KA, Hu HS, Price KAR, et al. Effect of the addition of temsirolimus to cetuximab in cetuximab-resistant head and neck cancers: results of the randomized PII MAESTRO study. J Clin Oncol. 2014;32(15 Suppl):6089.

    Article  Google Scholar 

  70. Bauman JE, Arias-Pulido H, Lee SJ, Fekrazad MH, Ozawa H, Fertig E, et al. A phase II study of temsirolimus and erlotinib in patients with recurrent and/or metastatic, platinum-refractory head and neck squamous cell carcinoma. Oral Oncol. 2013;49(5):461–7.

    Article  PubMed  PubMed Central  Google Scholar 

  71. Chung CH, Wang H, Tsottles N, Gourin CG, Agrawal N, Molinolo A, et al. A phase I study of everolimus in combination with cetuximab and cisplatin as first-line therapy in recurrent and metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). J Clin Oncol. 2012;30(15 Suppl):e16061.

    Google Scholar 

  72. Adkins D, Oppelt PJ, Ley JC, Trinkaus K, Neupane PC, Sacco AG. Multicenter phase II trial of palbociclib, a selective cyclin dependent kinase (CDK) 4/6 inhibitor, and cetuximab in platinum-resistant HPV unrelated (−) recurrent/metastatic head and neck squamous cell carcinoma (RM HNSCC). J Clin Oncol. 2018;36:6008.

    Article  Google Scholar 

  73. Cohen EEW, Soulieres D, Le Tourneau C, Dinis J, Licitra L, Ahn MJ, et al. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. Lancet. 2019;393(10167):156–67.

    Article  PubMed  Google Scholar 

  74. Ferris RL, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 2016;375(19):1856–67.

    Article  PubMed  PubMed Central  Google Scholar 

  75. Zandberg DP, Algazi AP, Jimeno A, Good JS, Fayette J, Bouganim N, et al. Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with >/=25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy. Eur J Cancer. 2019;107:142–52.

    Article  PubMed  Google Scholar 

  76. Shiono S, Kawamura M, Sato T, Okumura S, Nakajima J, Yoshino I, et al. Pulmonary metastasectomy for pulmonary metastases of head and neck squamous cell carcinomas. Ann Thorac Surg. 2009;88(3):856–60.

    Article  PubMed  Google Scholar 

  77. Liu D, Labow DM, Dang N, Martini N, Bains M, Burt M, et al. Pulmonary metastasectomy for head and neck cancers. Ann Surg Oncol. 1999;6(6):572–8.

    Article  PubMed  Google Scholar 

  78. Mochizuki T, Okumura S, Ishii G, Ishikawa Y, Hayashi R, Kawabata K, et al. Surgical resection for oral tongue cancer pulmonary metastases. Interact Cardiovasc Thorac Surg. 2010;11(1):56–9.

    Article  PubMed  Google Scholar 

  79. Lopez-Verdin S, Lavalle-Carrasco J, Carreon-Burciaga RG, Serafin-Higuera N, Molina-Frechero N, Gonzalez-Gonzalez R, et al. Molecular markers of anticancer drug resistance in head and neck squamous cell carcinoma: a literature review. Cancers. 2018;10(10):pii: E376.

    Article  Google Scholar 

  80. Becker M, Levy D. Modeling the transfer of drug resistance in solid tumors. Bull Math Biol. 2017;79(10):2394–412.

    Article  PubMed  Google Scholar 

  81. Quintela-Fandino M, Hitt R, Medina PP, Gamarra S, Manso L, Cortes-Funes H, et al. DNA-repair gene polymorphisms predict favorable clinical outcome among patients with advanced squamous cell carcinoma of the head and neck treated with cisplatin-based induction chemotherapy. J Clin Oncol. 2006;24(26):4333–9.

    Article  PubMed  Google Scholar 

  82. Cutilli T, Leocata P, Dolo V, Altobelli E. Evaluation of p53 protein as a prognostic factor for oral cancer surgery. Br J Oral Maxillofac Surg. 2013;51(8):922–7.

    Article  PubMed  Google Scholar 

  83. Blons H, Gad S, Zinzindohoue F, Maniere I, Beauregard J, Tregouet D, et al. Matrix metalloproteinase 3 polymorphism: a predictive factor of response to neoadjuvant chemotherapy in head and neck squamous cell carcinoma. Clin Cancer Res. 2004;10(8):2594–9.

    Article  PubMed  Google Scholar 

  84. Ansell A, Jedlinski A, Johansson AC, Roberg K. Epidermal growth factor is a potential biomarker for poor cetuximab response in tongue cancer cells. J Oral Pathol Med. 2016;45(1):9–16.

    Article  PubMed  Google Scholar 

  85. Roepstorff K, Grandal MV, Henriksen L, Knudsen SL, Lerdrup M, Grovdal L, et al. Differential effects of EGFR ligands on endocytic sorting of the receptor. Traffic. 2009;10(8):1115–27.

    Article  PubMed  PubMed Central  Google Scholar 

  86. Setubal Destro Rodrigues MF, Gammon L, Rahman MM, Biddle A, Nunes FD, Mackenzie IC. Effects of cetuximab and erlotinib on the behaviour of cancer stem cells in head and neck squamous cell carcinoma. Oncotarget. 2018;9(17):13488–500.

    PubMed  PubMed Central  Google Scholar 

  87. Gemenetzidis E, Gammon L, Biddle A, Emich H, Mackenzie IC. Invasive oral cancer stem cells display resistance to ionising radiation. Oncotarget. 2015;6(41):43964–77.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Oncology, McGil University, Montreal, QC, Canada

    Arielle Elkrief & Nathaniel Bouganim

  2. Department of Oral and Maxillofacial Surgery, McGil University, Montreal, QC, Canada

    Nicholas Makhoul

Authors
  1. Arielle Elkrief
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nicholas Makhoul
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Nathaniel Bouganim
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nathaniel Bouganim .

Editor information

Editors and Affiliations

  1. Department of Oral and Maxillofacial Surgery, North Memorial Medical Center, Minneapolis, MN, USA

    Deepak Kademani

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Elkrief, A., Makhoul, N., Bouganim, N. (2020). Novel and Emerging Chemotherapeutic Agents in Head and Neck Cancer. In: Kademani, D. (eds) Improving Outcomes in Oral Cancer. Springer, Cham. https://doi.org/10.1007/978-3-030-30094-4_9

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-30094-4_9

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-30093-7

  • Online ISBN: 978-3-030-30094-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation